Cannabinoids for symptom management in children with cancer : A systematic review and meta-analysis
© 2023 The Authors. Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society..
BACKGROUND: Despite the widespread use of medical cannabis, little is known regarding the safety, efficacy, and dosing of cannabis products in children with cancer. The objective of this study was to systematically appraise the existing published literature for the use of cannabis products in children with cancer.
METHODS: This systematic review, registered with the International Prospective Register of Systematic Reviews (CRD42020187433), searched four databases: MEDLINE, Embase, PsycINFO, and the Cochrane Library. Abstracts and full texts were screened in duplicate. Data on types of cannabis products, doses, formulations, frequencies, routes of administration, indications, and clinical and demographic details as well as reported efficacy outcomes were extracted. Data on cannabinoid-related adverse events were also summarized.
RESULTS: Out of 34,611 identified citations, 19 unique studies with a total of 1927 participants with cancer were included: eight retrospective chart reviews, seven randomized controlled trials, two open-label studies, and two case reports. The included studies reported the use of various cannabis products for the management of symptoms. Cannabinoids were commonly used for the management of chemotherapy-induced nausea and vomiting (11 of 19 [58%]). In controlled studies, somnolence, dizziness, dry mouth, and withdrawal due to adverse events were more commonly associated with the use of cannabinoids. Across all included studies, no serious cannabis-related adverse events were reported.
CONCLUSIONS: Although there is evidence to support the use of cannabis for symptom management, in children with cancer, there is a lack of rigorous evidence to inform the dosing, safety, and efficacy of cannabinoids. Because of the increasing interest in using cannabis, there is an urgent need for more research on medical cannabis in children with cancer.
| Errataetall: |
CommentIn: Cancer. 2023 Nov 15;129(22):3522-3524. - PMID 37641180 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:129 |
|---|---|
| Enthalten in: |
Cancer - 129(2023), 22 vom: 15. Nov., Seite 3656-3670 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chhabra, Manik [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 30.10.2023 Date Revised 21.03.2024 published: Print-Electronic CommentIn: Cancer. 2023 Nov 15;129(22):3522-3524. - PMID 37641180 Citation Status MEDLINE |
|---|
| doi: |
10.1002/cncr.34920 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361335768 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361335768 | ||
| 003 | DE-627 | ||
| 005 | 20240323000127.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/cncr.34920 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1341.xml |
| 035 | |a (DE-627)NLM361335768 | ||
| 035 | |a (NLM)37635461 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chhabra, Manik |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cannabinoids for symptom management in children with cancer |b A systematic review and meta-analysis |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.10.2023 | ||
| 500 | |a Date Revised 21.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Cancer. 2023 Nov 15;129(22):3522-3524. - PMID 37641180 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 The Authors. Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society. | ||
| 520 | |a BACKGROUND: Despite the widespread use of medical cannabis, little is known regarding the safety, efficacy, and dosing of cannabis products in children with cancer. The objective of this study was to systematically appraise the existing published literature for the use of cannabis products in children with cancer | ||
| 520 | |a METHODS: This systematic review, registered with the International Prospective Register of Systematic Reviews (CRD42020187433), searched four databases: MEDLINE, Embase, PsycINFO, and the Cochrane Library. Abstracts and full texts were screened in duplicate. Data on types of cannabis products, doses, formulations, frequencies, routes of administration, indications, and clinical and demographic details as well as reported efficacy outcomes were extracted. Data on cannabinoid-related adverse events were also summarized | ||
| 520 | |a RESULTS: Out of 34,611 identified citations, 19 unique studies with a total of 1927 participants with cancer were included: eight retrospective chart reviews, seven randomized controlled trials, two open-label studies, and two case reports. The included studies reported the use of various cannabis products for the management of symptoms. Cannabinoids were commonly used for the management of chemotherapy-induced nausea and vomiting (11 of 19 [58%]). In controlled studies, somnolence, dizziness, dry mouth, and withdrawal due to adverse events were more commonly associated with the use of cannabinoids. Across all included studies, no serious cannabis-related adverse events were reported | ||
| 520 | |a CONCLUSIONS: Although there is evidence to support the use of cannabis for symptom management, in children with cancer, there is a lack of rigorous evidence to inform the dosing, safety, and efficacy of cannabinoids. Because of the increasing interest in using cannabis, there is an urgent need for more research on medical cannabis in children with cancer | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Meta-Analysis | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a cancer symptoms | |
| 650 | 4 | |a cannabidiol | |
| 650 | 4 | |a chemotherapy-induced nausea and vomiting | |
| 650 | 4 | |a children | |
| 650 | 4 | |a medical cannabis | |
| 650 | 4 | |a tetrahydrocannabinol | |
| 650 | 7 | |a Cannabinoids |2 NLM | |
| 650 | 7 | |a Medical Marijuana |2 NLM | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 700 | 1 | |a Ben-Eltriki, Mohamed |e verfasserin |4 aut | |
| 700 | 1 | |a Paul, Arun |e verfasserin |4 aut | |
| 700 | 1 | |a Lê, Mê-Linh |e verfasserin |4 aut | |
| 700 | 1 | |a Herbert, Anthony |e verfasserin |4 aut | |
| 700 | 1 | |a Oberoi, Sapna |e verfasserin |4 aut | |
| 700 | 1 | |a Bradford, Natalie |e verfasserin |4 aut | |
| 700 | 1 | |a Bowers, Alison |e verfasserin |4 aut | |
| 700 | 1 | |a Rassekh, S Rod |e verfasserin |4 aut | |
| 700 | 1 | |a Kelly, Lauren E |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer |d 1948 |g 129(2023), 22 vom: 15. Nov., Seite 3656-3670 |w (DE-627)NLM000028649 |x 1097-0142 |7 nnns |
| 773 | 1 | 8 | |g volume:129 |g year:2023 |g number:22 |g day:15 |g month:11 |g pages:3656-3670 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/cncr.34920 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 129 |j 2023 |e 22 |b 15 |c 11 |h 3656-3670 | ||